CEOs of The LYCRA Company & Qore join Global Fashion Summit lineup
The LYCRA Company, a global leader in developing sustainable fibers and solutions for the apparel industry, announced that its CEO, Gary Smith, is a speaker at the Global Fashion Summit: Copenhagen Edition 2025. He will be joined on stage by Jon Veldhouse, CEO of Qore, the maker of QIRA, a next-generation BDO and a key ingredient in bio-derived LYCRA fiber, which is launching later this year.
The LYCRA Company and Qore will debut at the Global Fashion Summit 2025 in Copenhagen, with CEOs Gary Smith and Jon Veldhouse discussing their new bio-derived LYCRA fibre made with QIRA. Launching later this year, the fibre uses corn-based BDO, offers 70 per cent renewable content, and can cut LYCRA's carbon footprint by up to 44 per cent, requiring no fabric or process changes.
Smith and Veldhouse will discuss the development of this sustainable fiber made from annually renewable field corn during their Fireside Chat: From Farm to Fashion. Their session takes place on Wednesday, June 4, at 3:35 CEST in the DR Concert Hall. The discussion will be moderated by Amy Nguyen, a researcher, writer, and founder of Sustainable & Social.
This is the first time both companies are participating in the Global Fashion Summit, a premier platform focused on sustainability in the fashion industry. The companies have a prominent exhibit space for attendees to learn more about bio-derived LYCRA fiber made with QIRA. Here, visitors can be transported to the Qore site and cornfields in Iowa through a virtual reality experience.
Bio-derived LYCRA EcoMade fiber will be the world's first large-scale, commercially available renewable elastane. It delivers equivalent performance to the original LYCRA fiber and serves as a one-to-one replacement with no re-engineering of fabrics, processes, or garment patterns required. The product contains 70 percent renewable content and can potentially reduce the carbon footprint of LYCRA fiber by up to 44 percent. The LYCRA Company holds patents related to this renewable fiber in several regions including Europe.
'We're proud to join the Global Fashion Summit for the first time and showcase how collaboration can accelerate a more sustainable future for fashion,' said Gary Smith, CEO of The LYCRA Company. 'Partnering with Qore has enabled us to scale innovation that is renewable and ready to meet the demands of global fashion brands striving to meet their sustainability goals.'
The newly constructed Qore site in Eddyville, Iowa, began operating last month and has started producing QIRA. The company will host a grand opening celebration in July.
'Starting production at our new state-of-the-art facility marks a major step forward—not just for Qore, but for the entire industry,' said Jon Veldhouse, CEO of Qore. 'With QIRA now being made in Iowa from annually renewable field corn, we're turning sustainable innovation into reality and helping our partners bring next-generation materials to market.' Note: The headline, insights, and image of this press release may have been refined by the Fibre2Fashion staff; the rest of the content remains unchanged.
Fibre2Fashion News Desk (HU)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fashion Value Chain
a day ago
- Fashion Value Chain
RE&UP Accelerates Circular Textiles at Global Industry Events
In a defining week for sustainable fashion, RE&UP, a trailblazer in recycled polycotton solutions, took center stage at two premier international forums: the Global Fashion Summit in Copenhagen and the Textiles Recycling Expo in Brussels. Uniting innovation with impact, the company brought forward critical insights on next-gen materials, textile recycling, and the infrastructure required to scale circularity. At the Global Fashion Summit, Andreas Dorner, General Manager at RE&UP, contributed to the Fibre Futures panel on the Ignite Stage, sharing deep insights into polycotton innovation. 'When it comes to polycotton, RE&UP is the go-to solution provider,' Dorner stated, reinforcing the company's expertise in tackling one of the industry's most complex blended fabrics. Meanwhile, Ebru Özküçük Guler, Chief Sustainability Officer, moderated a high-impact session titled What is Next-Gen?, featuring speakers from the European Environment Agency and Fashion for Good. 'The shift to next-gen materials isn't just about innovation,' she emphasized, 'it's about building the systems to scale them responsibly.' In Brussels, at the Textiles Recycling Expo, RE&UP's Marco Lucietti, Head of Global Marketing and Communications, joined a panel discussion on Scaling Recycled Content: Turning Ambition into Industry Reality. His insights tackled the need for robust infrastructure, policy alignment, and investment to turn promises into performance. 'The energy was high and the message was clear: it's time to turn circularity from a commitment into a capability,' Lucietti shared. Across both events, RE&UP's message resonated strongly: innovation without scalability and accountability is not enough. From pioneering recycled polycotton applications to shaping circular infrastructure, RE&UP continues to turn bold ideas into transformative action. As textile sustainability accelerates into a new era, RE&UP remains committed to pushing boundaries, sparking dialogue, and delivering solutions that turn theory into impact.
Time of India
2 days ago
- Time of India
Dr Reddys Share Price Live Updates: Strong performance for Dr. Reddy's Laboratories
20 Jun 2025 | 08:43:52 AM IST Stay up-to-date with the Dr Reddys Stock Liveblog, your trusted source for real-time updates and thorough analysis of a prominent stock. Explore the latest details on Dr Reddys, including: Last traded price 1326.1, Market capitalization: 110657.13, Volume: 1654212, Price-to-earnings ratio 19.57, Earnings per share 67.77. Get a comprehensive understanding of Dr Reddys with our coverage of both fundamental and technical indicators. Stay informed about breaking news that can have a significant impact on Dr Reddys's performance. Our expert opinions and recommendations empower you to make well-informed investment choices. Trust the Dr Reddys Stock Liveblog to keep you informed and equipped in the dynamic market landscape. The data points are updated as on 08:43:52 AM IST, 20 Jun 2025 Show more
Mint
3 days ago
- Mint
Ozempic, a patent challenge, and the $25 billion race for India's weight-loss drug market
Mumbai: In late May, Dr. Reddy's Laboratories, a pharmaceutical company from Hyderabad, sprang a surprise. It filed a patent challenge against Novo Nordisk, a Danish company, for its popular weight loss drug semaglutide. Novo Nordisk filed for two patent applications in India—in 2006, which expired in September 2024, and another in 2007, which is set to expire in March 2026. Dr. Reddy's has challenged the second patent, contending that it lacks novelty. Pharma companies often file follow-on patents with claims of modifications to the original compound and its derivative forms. The follow-on patents allow drug developers to extend their market monopoly and halt generic competition for longer. Generic versions are cheaper copies of the original drug. Dr. Reddy's, obviously, is in a hurry to launch a generic version. A win for the company will upend the plans of more than a dozen local pharmaceutical firms, all of whom are eyeing a slice of the estimated $25 billion Indian weight loss market. No prescription drug in recent memory has captured the imagination of Indian patients as much as semaglutide. Or for that matter globally. In 2024, sold under three brand names—Ozempic, Wegovy and Rybelsus—semaglutide is the second most prescribed drug in the world, notching sales of $29 billion annually. A more recently launched competing brand, Mounjaro, by US-headquartered drug maker Eli Lilly, grew 123% in 2024 to $11.5 billion and is already among the top 10 drugs in the world, according to Drug Discovery & Development, a pharmaceutical industry news website. 'It's a big opportunity. It's a product that comes once in a while in the pharma cycle, and perhaps a product that people are a lot more aware of, much before its launch," Umang Vohra, managing director and global CEO of Cipla, told journalists during an interaction last month. Social media has contributed immensely to the street popularity of Ozempic, largely driven by celebrity endorsements by the likes of Oprah Winfrey and Elon Musk. Both admitted to using such drugs to manage their weight. Though Indian celebrities haven't yet admitted to their use, the mystery slimming of Bollywood film maker Karan Johar and TV talk show host Kapil Sharma have drawn comparisons. Opportunity 2.0 Nonetheless, it is not all social media. There is a genuine market for weight loss medications—numbers tell the story. A recent Lancet study stated that India is expected to total 450 million overweight or obese people by 2050, the largest in the world. The study also found that obesity rates increased from 1.2% in 1990 to 9.8% in 2022 for women and 0.5% to 5.4% in men. Those with body mass index (BMI) between 25 kg/m2 to 29.9 kg/m2 are considered overweight while those with an index of over 30 kg/m2 are considered obese. 'Often, lifestyle diseases are associated with adults but we must not overlook the increasing issues of overweight and obesity in juveniles. It is a growing menace," said Dr Sambit Patnaik, a Mumbai-based surgeon. The pharmaceutical industry has also spotted a rare opportunity, similar to the one it saw in anti-diabetic drugs at the turn of the century. At that time, the Indian pharmaceutical market, according to market research agency MARG, was all of ₹16,000 crore and diabetic drugs accounted for about ₹1,000 crore of it. Today, the market for diabetic drugs is worth ₹40,000 crore and it accounts for roughly 10% of the ₹4 trillion Indian industry. Back then, the boom was aided by the generic version of metformin, an oral drug with lower gastric side effects for type 2 diabetes. It caught the fancy of Ranbaxy Laboratories, Dr. Reddy's, Glenmark Pharmaceuticals and a host of other Indian pharmaceutical companies. Like diabetes drugs, weight loss medications also have to be taken as long as a patient wants to manage her or his weight—which explains the current gold rush. Crash the price In India, generic versions can cut current prices substantially, thereby expanding the market. Novo Nordisk's Rybelsus is available in India but only in oral form and a month's supply costs ₹10,000. The most effective form of the drug is as an injectable, and it is delivered in metered doses using a pen-like device with thin hair like needles. Imports can cost upwards of ₹80,000 per month. The injectable version is expected to launch soon. Despite the high costs, Rybelsus sales have notched up ₹418 crore, between its launch in 2022 and March 2025, according to Pharma data agency IQVIA. Mounjaro's injectables, available in India, cost far less— ₹17,500 per month. 'Since India sells branded generic dosages, the retail price of new launches will be 40-70% of the innovator's price," Ravinder Singha, managing director of Firmlink Pharma, a generic exporter, said. 'But since Mounjaro is the benchmark treatment, we should expect semaglutide drugs to be substantially cheaper," he added. Semaglutide tablets, therefore, could be available for ₹4000- ₹7000 per month and Wegovy clones at a bigger discount to Mounjaro's ₹17,500 per month. 'Generic brands in India will hit the shelf the next day a drug goes off patent," said Nimish Mehta, founder of Research Delta Advisors, a pharma consultancy. So, Indian generics should be available from April 2026 onwards. Meanwhile, Indian pharmacies have acknowledged the growing demand for such drugs. 'These GLP-1s…everyday we are selling huge quantities," Shobana Kamineni, executive chairperson of Apollo Health Co and Apollo Pharmacies, said. Medications used to treat obesity and type 2 diabetes are classified as GLP-1 (glucagon-like peptide-1) drugs. The science GLP-1 is an equivalent of peptide glucagon that is produced in the small intestine and colon after ingestion of food which increases blood sugar. Glucagon then stimulates the pancreas to produce insulin to control blood sugar. GLP-1 drugs behave like synthetic glucagon and stimulate the same effects from the body. In addition, GLP-1 drugs leave the user with a feeling of fullness that sends a message to the brain to slow down the ingestion of food. From the last decade, there is enough evidence that the new class of GLP-1 drugs, like semaglutide and tirzepatide, offer weight reduction between 21-23% of the initial body weight without any severe side effects. And as anti-diabetic drugs, they were meant for prolonged use. 'In the range of medication for management of obesity, (GLP-1s) have proven to be the game changer," bariatric surgeon Dr Muffazal Lakdawala told Mint. Historically, GLP-1 class of drugs did not see much competition for two reasons. Initially, these drugs were marketed as an anti-diabetic injection—there were already many competing drugs available in that space. Second, glucagon being a peptide hormone, an organic substance, the drugs had to emulate their form and structure. Like insulin, they can be produced by fermentation or by chemical synthesis and both have their complexities. Producing large quantities of fermentation medicines like insulin or penicillin require high investments, both in manufacturing and cold supply chains. Even in the oral version of semaglutide, which is manufactured by chemical synthesis, the manufacturing process is a long and complex one. Oral delivery of peptides does not permeate the gastrointestinal tract easily and, therefore, Novo Nordisk had to engineer its product differently to ensure potency. US dreams Despite all the complexities, Indian companies want to grab the opportunity the US, global and Indian markets present. Let's look at the US first. Companies like Sun Pharma, Dr. Reddy's, Lupin and Natco Pharma (which has a tie-up with Mylan Pharmaceuticals) filed applications with the US Food and Drug Administration (FDA) to make the generic versions of semaglutide the same month—December 2021. They did so to avail what is called the first-to-file (FTF) status. Overall, 18 Indian companies have applied. Generic applications in the US are filed way before patents expire and an FTF allows a company to market its generic for 180 days exclusively in the US, before more cheaper generics hit the market. Natco (through Mylan) is the only company to have sought approval for generic Wegovy. The US FDA has not yet approved any generic so far. 'Since an application to the FDA will include a sample of the product and details of manufacturing plants, we can assume that there is enough confidence among Indian players to make the drug," Mehta of Research Delta Advisors said. India stack A long list of companies, from different pharma sub-sectors, could benefit from the weight-loss bonanza. For the domestic market and for generic exports to countries where no patents exist, the list of companies waiting to launch semaglutide next year includes Dr. Reddy's, Sun Pharma, Cipla, Zydus Lifesciences, Lupin, Mankind Pharma, Alkem Laboratories, Biocon, Aurobindo Pharma, Natco and Torrent Pharmaceuticals among others. Zydus Lifesciences is working on a single pen device in multiple strengths, The Economic Times reported last month. It is also working on a novel formulation for semaglutide to commercialize in India and other markets. 'We are on track for day one launch in India," managing director Sharvil Patel told investors during an earnings call last month. Cipla, meanwhile, is eyeing the launch of GLP-1s through partnerships as well as through its own generic version. In a post-earnings media interaction recently, the company's managing director and global CEO Umang Vohra said: 'I think the biggest opportunity for us, at least, would continue to be the Indian market." Biocon has already launched another GLP-1, liraglutide, in India earlier this month. 'Our strategy is to offer liraglutide at competitive prices, aligned with local healthcare economics to maximize patient access in India," a company spokesperson told Mint in an email response. Biocon plans to launch semaglutide in India mid-next year, CEO Siddharth Mittal had told Mint in an earlier interview. The company now plans to expand its manufacturing capabilities to ensure supply reliability, it said in the emailed response. Sun Pharma and Mankind are also working on their own novel anti-obesity drugs. Sun Pharma is working on a novel GLP-1 GL0034 called utreglutide, which will likely be commercialized by the end of this decade. Mankind's drug candidate, GRP119, is currently in phase 2 trials in Australia. For the generic version of semaglutide, the company is banking on its salesforce and reach to give it a competitive edge, managing director Rajeev Juneja told Mint in an earlier interview. 'Any doctor would want to prescribe it, because now people know that there is something called Mounjaro, or semaglutide or Ozempic," Juneja said. 'We, by default, have a natural advantage because we have the deepest coverage, we have the maximum number of people working in each division," he added. Further, players like Divi's Laboratories, a manufacturer of active pharmaceutical ingredients, and Syngene International, a contract research, development and manufacturing company, can also benefit from the gold rush. 'Divi's Laboratories will be a key beneficiary in GLP-1 manufacturing as it makes several components in the peptide sequence," Shrikant Akolkar, head of pharmaceutical research at Nuvama, a brokerage, said. OneSource Specialty Pharma, the contract development and manufacturing arm of Strides Pharma, is among the few companies with end-to-end capabilities for GLP-1s—from formulation to device assembly. 'The most complex part of the whole value chain is to assemble the pen devices," OneSource Pharma's CEO, Neeraj Sharma, told Mint during a recent interaction. Another company, Vadodara-based Shaily Engineering Plastics, says it is nearly doubling its manufacturing line to make injectable pens—from 45 million to 85 million—funded by customer advances. A caution Clearly, speed to market will separate the winners from the also-rans. 'Early movers among the Indian players stand a good chance to benefit from GLP-1," said Akolkar. A recent report by Nuvama put a buy on Dr. Reddy's and Divi's Laboratories and a hold on Natco Pharma based on their GLP-1 play. Nonetheless, some doctors fear misuse of the drug because of its popularity. A prescription for diabetic drugs can be written by any medical practitioner. Weight loss clinics in the unorganised sector could start dispensing the drug for cosmetic purposes. For instance, a person in her 20s, who is slightly overweight, may be tempted to use these drugs instead of trying to lose weight by making lifestyle changes. 'We need some regulations to prevent over-the-counter use for weight loss," Dr Muffazal Lakdawala said. 'It is a hormonal drug so you have to be a little careful."
